Chemo drug delays thyroid cancer; Antigen gains $2.5M for vaccine work; Exiting Roche staffers get some TLC;

Conversation on Twitter :

 @FierceBiotech: When Herceptin gets under the skin--literally. More | Follow @FierceBiotech

 @JohnCFierce: AstraZeneca hands over $28M to team with Regulus on cardio pact. More | Follow @JohnCFierce

 @RyanMFierce: What does translational research mean in practice? Here's a good piece from the front lines in the U.K. More | Follow @RyanMFierce

> A new study indicates that the chemo drug vandetanib delayed the development of advanced thyroid cancer. "This study is confirmation that vandetanib is effective in advanced thyroid cancer patients, not only in terms of overall response, but also in terms of progression-free survival," said lead researcher Dr. Martin Schlumberger, of the Institut Gustave Roussy in Villejuif, France. "Vandetanib should be used as first-line treatment in patients with progressive, untreatable thyroid cancer." Story

> About half of the 1,000 staffers being laid off from Roche's big R&D complex in New Jersey have gone through the company's new career transition center. It's called the Transition and Learning Center--or TLC. Story

> Antigen Discovery has won a $2.5 million grant to work on a new malaria vaccine. Story

> Genocea Biosciences announced today that it has initiated a Phase I/IIa clinical study with its lead candidate, GEN-003. Release

> Dynavax Technologies named Christine Larson to the position of vice president and CFO. Release

Pharma News

 @FiercePharma: Watson sues FDA for delay of generic Actos launch. More | Follow @FiercePharma

> New pharma trial: Pfizer, GSK, J&J test 1-page drug information sheets. News

> GSK sells off more low-margin brands as it focuses on HGS. Article

> Lawmakers pressure Gilead on Quad price ahead of approval. Story

Medical Device News

 @FierceMedDev: Venture capital funding for medical device firms declined 17% in Q2, according to PwC. More | Follow @FierceMedDev

 @MarkHFierce: An AdvaMed job placement initiative for military veterans has snagged some funding. Formal launch is at AdvaMed 2012. More | Follow @MarkHFierce

 @DamianFierce: KCI is selling its therapeutic support systems business for $275M. More | Follow @DamianFierce

> Speculation reigns on Medtronic M&A targets in China. Story

> Medical device VC shrank by 17% in Q2, PwC says. Article

Biomarkers News

> Drug-biomarker combo pinpoints prostate cancer. Story

> Genes pinpoint kids' bone cancer outcomes. News

> Alzheimer's disease blood test comes ever closer. Article

> Urine proteomics could pinpoint diabetic nephropathy. More

Drug Delivery News

> pSivida--focusing on delivery to the eye. Editor's Corner

> Oral nanoparticle vaccine could protect against HIV. Spotlight

> Hydrogel foams can deliver drugs for 6 months. More

> Nanoplexes deliver personalized medicine in cancer. Story

And Finally… Investigators at Harvard Medical School have set out to find why women are three times more likely than men to suffer from migraines. Story

 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.